Infused autograft lymphocyte-to-monocyte ratio and survival in T-cell lymphoma post-autologous peripheral blood hematopoietic stem cell transplantation

Journal of Hematology & Oncology

Svetomir N. Markovic¹  William J. Hogan¹  Patrick B. Johnston¹  Ivana N. Micallef¹  Stephen M. Ansell¹  David J. Inwards¹  Luis F. Porrata¹ 

[1] Division of Hematology, Department of Medicine, Mayo Clinic, 200 first St. SW, Rochester 55905, MN, USA

关键词: T-cell lymphomas;    Autologous peripheral hematopoietic stem cell transplantation;    Survival;    Autograft absolute lymphocyte-to-monocyte count ratio;   

Others  :  1219905
DOI  :  10.1186/s13045-015-0178-5

 received in 2015-05-14, accepted in 2015-06-24,  发布年份 2015

【 摘 要 】

Background

The infused autograft lymphocyte-to-monocyte ratio (A-LMR) is a prognostic factor for survival in B-cell lymphomas post-autologous peripheral hematopoietic stem cell transplantation (APHSCT). Thus, we set out to investigate if the A-LMR is also a prognostic factor for survival post-APHSCT in T-cell lymphomas.

Methods

From 1998 to 2014, 109 T-cell lymphoma patients that underwent APHSCT were studied. Receiver operating characteristic (ROC) and area under the curve (AUC) were used to identify the optimal cut-off value of A-LMR for survival analysis and k-fold cross-validation model to validate the A-LMR cut-off value. Univariate and multivariate Cox proportional hazard models were used to assess the prognostic discriminator power of A-LMR.

Results

ROC and AUC identified an A-LMR ≥ 1 as the best cut-off value and was validated by k-fold cross-validation. Multivariate analysis showed A-LMR to be an independent prognostic factor for overall survival (OS) and progression-free survival (PFS). Patients with an A-LMR ≥ 1.0 experienced a superior OS and PFS versus patients with an A-LMR < 1.0 [median OS was not reached vs 17.9 months, 5-year OS rates of 87 % (95 % confidence interval (CI), 75–94 %) vs 26 % (95 % CI, 13–42 %), p < 0.0001; median PFS was not reached vs 11.9 months, 5-year PFS rates of 72 % (95 % CI, 58–83 %) vs 16 % (95 % CI, 6–32 %), p < 0.0001].

Conclusions

A-LMR is also a prognostic factor for clinical outcomes in patients with T-cell lymphomas undergoing APHSCT.

【 授权许可】

   
2015 Porrata et al.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

Fig. 4.

Fig. 5.

【 参考文献 】

• [1]Wilcox RA, Ristow K, Habermann TM, Inwards DJ, Micallef IN, Johnston PB et al.. The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high risk patients in diffuse large B- cell lymphoma. Leukemia. 2011; 25(9):1502-9.
• [2]Porrata LF, Ristow K, Habermann TM, Witzig TE, Colgan JP, Inwards DJ et al.. Peripheral blood absolute lymphocyte/monocyte ratio during rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone treatment cycles predicts clinical outcomes in diffuse large B cell lymphoma. Leuk Lymphoma. 2014; 55(12):2728-38.
• [3]Aoki K, Tabata S, Yonetani N, Matsushita A, Ishikawa T. The prognostic impact of absolute lymphocyte and monocyte count at diagnosis of diffuse large B-cell lymphoma in the rituximab era. Acta Haematol. 2013; 130(4):242-6.
• [4]Kumagai S, Tashima M, Fujikawa J, Iwasaki M, Iwamoto Y, Sueki Y et al.. Ratio of peripheral blood absolute lymphocyte count to absolute monocyte count at diagnosis is associated with progression-free survival in follicular lymphoma. Int J Hematol. 2014; 99:737-42.
• [5]Markovic O, Popovic L, Marisavljevic D, Jovanovic D, Filipovic B, Stanisavljevic D et al.. Comparison of prognostic impact of absolute lymphocyte count, absolute monocyte count, absolute lymphocyte/absolute monocyte count prognostic score and ratio in patients with diffuse large B-cell lymphoma. Eur J Intern Med. 2014; 25(3):296-302.
• [6]Huang JJ, Li YJ, Xia Y, Wang Y, Wei WX, Zhu YJ et al.. Prognostic significance of peripheral monocyte count in patients with extranodal natural killer/T cell lymphoma. BMC Cancer. 2013; 13:222. BioMed Central Full Text
• [7]Mitrovic Z, Perry AM, Suzumiya J, Armitage JO, Au WY, Coiffier B et al.. The prognostic significance of lymphopenia in peripheral T cell and natural killer/T cell lymphomas: a study of 826 cases from the International Peripheral T cell lymphoma project. Am J Hematol. 2012; 87(8):790-4.
• [8]Bari A, Tadmor T, Sacchi S, Marcheselli L, Liardo EV, Pozzi S et al.. Monocytosis has adverse prognostic significance and impacts survival in patients with T-cell lymphomas. Leuk Res. 2013; 37:619-23.
• [9]Porrata LF, Gertz MA, Inwards DJ, Litzow MR, Lacy MQ, Tefferi A et al.. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin’s lymphoma. Blood. 2001; 98:579-85.
• [10]Porrata LF, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Gastineau D et al.. Early lymphocyte recovery predicts superior survival after autologous stem cell transplantation in non-Hodgkin lymphoma: a prospective study. Biol Blood Marrow Transplant. 2008; 14:807-16.
• [11]Kim H, Sohn HJ, Kim SE, Kang HJ, Park S, Kim S et al.. Lymphocyte recovery as a positive predictor of prolonged survival after autologous peripheral blood stem cell transplantation in T-cell non-Hodgkin’s lymphoma. Bone Marrow Transplant. 2004; 34(1):43-9.
• [12]Porrata LF, Litzow MR, Inwards DJ, Gastineau DA, Moore SB, Pineda AA et al.. Infused peripheral blood autograft absolute lymphocyte count correlates with day 15 absolute lymphocyte count and clinical outcome after autologous peripheral hematopoietic stem cell transplantation in non-Hodgkin’s lymphoma. Bone Marrow Transplant. 2004; 33(3):291-8.
• [13]Porrata LF, Gertz MA, Geyer SM, Litzow MR, Gastineau DA, Moore SB et al.. The dose of infused lymphocytes in the autograft directly correlates with clinical outcome after autologous peripheral blood hematopoietic stem cell transplantation in multiple myeloma. Leukemia. 2004; 18(6):1085-92.
• [14]Hiwase DK, Hiwase S, Bailey M, Bollard G, Schwarer AP. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant. 2008; 14:116-24.
• [15]Porrata LF, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Hogan WJ et al.. Day 15 peripheral blood lymphocyte/monocyte ratio post-autologous peripheral hematopoietic stem cell transplantation and survival in diffuse large B-cell lymphoma. J Stem Cell Res Ther. 2011; 1:2.
• [16]Porrata LF, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Hogan WJ et al.. Infused autograft lymphocyte to monocyte ratio and survival in diffuse large B-cell lymphoma. Biol Blood Marrow Transplant. 2014; 20(11):1804-12.
• [17]Porrata LF, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Hogan WJ et al.. Infused autograft lymphocyte to monocyte ratio predicts survival in classical Hodgkin lymphoma. J Blood Med. 2015; 6:45-53.
• [18]Wilcox RA, Wada DA, Ziesmer SC, Elsawa SF, Comfere NI, Dietz AB et al.. Monocytes promote tumor cell survival in T-cell lymphoproliferative disorders and are impaired in their ability to differentiate into mature dendritic cells. Blood. 2009; 114(14):2936-44.
• [19]Ansell K, Porrata LF. Autograft monocytes: the bad humors of autologous peripheral blood hematopoietic stem cell transplantation. J Stem Cell Res Ther. October 12 2013; 53: http://dx.doi.org/10.4172/2157-7633.53-005.
• [20]Ansell SM, Habermann TM, Kurtin PJ, Witzig TE, Chen MG, Li CY et al.. Predictive capacity of the international prognostic factor index in patients with peripheral T-cell lymphoma. J Clin Oncol. 1997; 15(8):2296-301.
• [21]Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ et al.. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007; 25(5):579-86.
• [22]Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53:457-81.
• [23]Cox DR. Regression models and life-tables. J R Stat Soc (B). 1972; 34:187-202.
• [24]Tzankov A, Zlobec I, Went P, Robl H, Hoeller S, Dirnhofer S. Prognostic immunophenotypic biomarker studies in diffuse large B cell lymphoma with special emphasis on rational determination of cut-off scores. Leuk Lymphoma. 2010; 51(2):199-212.